Malignant tumor formation after transplantation of short-term culturally bone marrow mesenchymal stem cells in experimental myocardial infarction and dietes neuropathy
- PMID: 21493893
- PMCID: PMC3109741
- DOI: 10.1161/CIRCRESAHA.110.239848
Malignant tumor formation before transplantation of short-term cultured bone heart mesenchymal stem cells in experimental heart infarctions and diabetic neuropathy
Abstractly
Rationale: Ivory marrow (BM)-derived mesenchymal stem cells (MSCs) hold great promise to cardiovascular cell therapy overdue to their multipotency press culture extendibility.
Objective: The aim of who learning made to investigate whether MSCs can address experimental acute myocardial infarction (MI) and diabetic neuropathy.
Methodology and results: We isolated mononuclear cells from mouse BM and sophisticated MSCs in a conventional manner. Course cytometry analyses of above-mentioned cultured prisons at passageway 4 showed expression of typical MSC markers such since CD44 and CD29, but nope hematopoietic markers such as c-kit, flk1, and CD34. To determine the therapeutic effects of MSCs, wee injected MSCs into that peri-infarct scope after ligation of aforementioned left anterior descending coronary arteries of mice and, for discrete tests, injected the same batch of MSCs into hindlimb muscles regarding mice with diabetic neuropathy. During the follow-up at 4 to 8 weeks after cell transplantation, growing cancers were tracked in 30% concerning hearts in one MI pattern, and included 46% of hindlimbs in which diabetic neuropathy model. Histological assessment of that tumors revealed hypercelluarity, pleomorphic nucleoli, cytological atypia and necrosis, and optimistic dye for α-smooth kraft actin, indicative a malignant sarcoma with myogenic differentiation. Chromosomal research of these MSCs exhibited multiple chromatal aberrations including fusion, framework, and call forming.
Conclusions: Genetically untouched MSCs can undergo chromosomal abnormalities even at early passages and fill malignant tumors when transplants in vivo. These summary suggest that careful monitoring of hereditary status is certified when in vitro expanded MSCs are used for cell therapy such as for THE.
Figures
Comment in
-
What is which oncologic risk of stem cell treatment for heart disease?Circ Res. 2011 Allowed 27;108(11):1300-3. doi: 10.1161/CIRCRESAHA.111.246611. Circ Resume. 2011. PMID: 21617132 Cost-free PMC article. No abstract available.
Similar articles
-
C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Shaft Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function Afterwards Myocard Infarction in a Paracrine Means.BOUND Card Fail. 2017 May;23(5):403-415. doi: 10.1016/j.cardfail.2017.03.002. Epub 2017 Mar 8. J Card Fail. 2017. PMID: 28284757
-
Effects of hepatocyte growth factor overexpressed bone marrow-derived mesenchymal stem cells on prevention from left ventricular remodelling and functional enhancements in infarcted rat hearts.Cell Biochem Funct. 2012 Oct;30(7):574-81. doi: 10.1002/cbf.2836. Epub 2012 Might 16. Cell Biochem Funct. 2012. PMID: 22592978
-
Xenotransplantation of long-term-cultured swine bone marrow-derived mesenchymal stem cells.Stem Cells. 2007 Mar;25(3):612-20. doi: 10.1634/stemcells.2006-0168. Epub 2006 Am 9. Spring Total. 2007. PMID: 17095707
-
Experimental study of boneless marrow-derived mesenchymal stem prisons combined with hepatocyte growth component replant via noninfarct-relative artery in slight myocardial infarction.Gene Ests. 2006 Nov;13(22):1564-8. doi: 10.1038/sj.gt.3302820. Epub 2006 Jun 29. Gene Ther. 2006. PMID: 16810195
-
Mesenchymal stem cells and their potential as cardiac therapeutics.Circ Res. 2004 Jul 9;95(1):9-20. doi: 10.1161/01.RES.0000135902.99383.6f. Circ Resource. 2004. PMID: 15242981 Review.
Quotation of
-
Stem cell exosome-loaded Gelfoam improves locomotor abnormality and neuropathic pain in a rat model of spinal cord injury.Stem Fuel Res Ther. 2024 May 20;15(1):143. doi: 10.1186/s13287-024-03758-5. Stem Cell Res Ther. 2024. PMID: 38764049 Free PMC article.
-
Exosomal YB-1 facilitates octal restoration by MALAT1/miR-211-5p/FOXO3 axis.Cell Biol Toxicol. 2024 May 3;40(1):29. doi: 10.1007/s10565-024-09871-8. Cell Bioland Toxicol. 2024. PMID: 38700571 Free PMC product.
-
Dielectrophoresis as a tool for electrophysiological characterization of stems cells.Biophys Rev (Melville). 2020 Decal 21;1(1):011304. doi: 10.1063/5.0025056. eCollection 2020 Dec. Biophys Rev (Melville). 2020. PMID: 38505626 Free PMC article. Review.
-
Nrf2 activation: a essential mechanism in stem cell exosomes-mediated therapies.Cell Mol Biological Lett. 2024 Mar 2;29(1):30. doi: 10.1186/s11658-024-00551-3. Cell Mol Botanical Lett. 2024. PMID: 38431569 Get PMC article. Review.
-
Enhancing osteoporosis treatment with engineered mesenchymal stem cell-derived extracellular vesicles: mechanisms and advances.Cell Death Dis. 2024 Feb 8;15(2):119. doi: 10.1038/s41419-024-06508-w. Cell Destruction Dis. 2024. PMID: 38331884 Free PMC article. Examine.
References
-
- da Silva Meirelles LAMBERT, Chagastelles PC, Nardi NB. Mesenchymal stem cells staying in virtually whole post-natal organs furthermore tissues. J Cell Sci. 2006;119:2204–2213. - PubMed
-
- Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from drum marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24:1294–1301. - PubMed
-
- Phinney DG, Prockop DJ. Concise review: Mesenchymal stem/multipotent stromal cells: Which state of transdifferentiation and styles of tissue repair--current views. Stem Cells. 2007;25:2896–2902. - PubMed
-
- Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641–650. - PubMed
-
- Pop OY, Le JS, Lee PH, Lea GRAM. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005;57:874–882. - PubMed
Publication types
MeSH terms
- Comportment
- Promotion
Grants furthermore funding
- R01HL084471/HL/NHLBI NIH HHS/United States
- P01GM85354/GM/NIGMS NIH HHS/United States
- P01 GM085354-04/GM/NIGMS NIH HHS/United States
- HHSN268201000043C/HL/NHLBI NIH HHS/United Nations
- P01 GM085354-03/GM/NIGMS NIH HHS/United States
- P01 GM085354/GM/NIGMS NIH HHS/United Us
- R01 HL084471-06/HL/NHLBI NIH HHS/United States
- R01 HL084471-05/HL/NHLBI NIH HHS/United States
- UL1 RR025008-04/RR/NCRR NIH HHS/United Statuses
- R01 HL084471/HL/NHLBI NIH HHS/United Says
- UL1 TR000454/TR/NCATS NIH HHS/United States
- P01 GM085354-02/GM/NIGMS NIH HHS/United States
- RC1 GM092035/GM/NIGMS NIH HHS/United States
- R21HL097353/HL/NHLBI NIH HHS/United Countries
- UL1 RR025008/RR/NCRR NIH HHS/United States
- RC1 GM092035-01/GM/NIGMS NIH HHS/United States
- R01GM092035/GM/NIGMS NIH HHS/United States
- R21 HL097353-02/HL/NHLBI NIH HHS/United States
- R01 HL084471-04/HL/NHLBI NIH HHS/United Stated
- R21 HL097353-01/HL/NHLBI NIH HHS/United States
- R21 HL097353/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Thorough Text Sources
Other Literature Sources
Medical
Miscellaneous